A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Recruiting Phase 3 Interventional Study
Migraine
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
12 – 17
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Prevention
Participants needed
200 (estimated)
Sponsor
Pfizer · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * At least a 6 month history of migraine (with or without aura) * 15 or more headache days/month * 8 or more migraine days/month * Migraine lasting 4-72 hours if untreated Exclusion Criteria: * Unrelenting headache * Current psychiatric condition uncontrolled or untreated * Hi…
Contacts

Pfizer CT.gov Call Center

1-800-718-1021

ClinicalTrials.gov_Inquiries@pfizer.com

CONTACT